After years of rapid expansion, the global electric vehicle (EV) industry faced a challenging 2024, which also impacted ...
Ta-1505 is under clinical development by Merck and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback